Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.

You may also be interested in...



Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside

In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity

Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside

In a move designed to allay concerns about post-Wyeth integration challenges, Pfizer outlined on April 7 the leadership structure of the future entity

Pfizer Drafts A New “Org Chart” Post Wyeth Merger

Pfizer to appoint a number of key Wyeth execs to prominent positions post-merger, sending a clear signal that it is handling the integration of Wyeth differently from its previous acquisitions of Pharmacia and Warner Lambert.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel